Pliva Hrvatska D.o.o.

Plantex Ltd.

Teva Pharmaceutical Industries Limited

Teva Pharmaceuticals International Gmbh

Ratiopharm Gmbh

Assia Chemical Industries Ltd.

Ivax International Gmbh

Marina Ratkaj

Tomislav Biljan

Jasna Dogan

Yi Wang

Marina Marinković

Sara Morasi Pipercic

Paolo Simone Tiseni

Maja Matanovic Skugor

Maurizio Gallina

Paolo Angioletti

Leonid Metsger

Judith Aronhime

Wolfgang Albrecht

Vinod Kumar Kansal

Brijnath P Chaurasia

Tina Mundorfer

Richard Guserle

Julia Hrakovsky

Dirk Schenk

Jens Geier

Mihaela Tuksar

Miroslav Zegarac

Gustavo Frenkel

Naveen C Srivastav

Ralph Stefan

Oliver Franković

Claudia Lauer

Ramkaran Prajapati

Pavan V Kumar

Hans-Juergen Mika

Siva Rama Krishna Muppalla

Roman Safonov

Ashish Tripathi

Siva Muppalla

Brijnath Chaurasia

Naveen Srivastav

Pavan Kumar

Mihaela Tuskar

Solid state forms of Palbociclib dimesylate, processes for preparation thereof and use thereof for preparation of Palbociclib are disclosed.

Solid state forms of palbociclib dimesylate

The present disclosure relates to novel, safe and efficient processes for the synthesis of Pimavanserin and salts thereof, as well as novel intermediates that can be used in these processes.

Processes and intermediates for the preparation of Pimavanserin

Solid state forms of Palbociclib dimesylate

The present disclosure relates to novel, safe and efficient processes for the synthesis of Pimavanserin and salts thereof, as well as novel intermediates that can be used in these processes. 

The present disclosure encompasses solid state forms of Sofosbuvir, processes for their production, and pharmaceutical compositions thereof.

Solid state forms of sofosbuvir

The present disclosure encompasses crystalline forms of Afatininb di-maleate and methods of their use.

Crystalline forms of afatinib di-maleate

Provided are crystalline forms of O-desmethylvenlafaxine fumarate, methods for their preparation, and pharmaceutical composition thereof.

Crystal forms of O-desmethylvenlafaxine fumarate

The invention provides Saxagliptin Schiff bases, polymorphs of Saxagliptin and (1S,3S,5S)-2-[(2S)-2-propan-2-ylideneamino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile, processes for preparing Saxagliptin hydrates, and pharmaceutical compositions thereof.

Saxagliptin intermediates, saxagliptin polymorphs, and processes for preparation thereof

The invention provides polymorphs of Saxagliptin hydrochloride, processes for preparing polymorphs of Saxagliptin hydrochloride, and pharmaceutical compositions of polymorphs of Saxagliptin hydrochloride.

Polymorphs of Saxagliptin hydrochloride and processes for preparing them

Growing community of inventors

Zagreb, Croatia

Marina Ratkaj